AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to sunvozertinib, a lung cancer drug approved in the U.S. and China for NSCLC with EGFR exon 20 insertion mutations.
Back
AstraZeneca pays Dizal $600M for global rights to lung cancer drug
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to sunvozertinib, a lung cancer drug, the Chinese drugmaker said Tuesday.
"With this agreement, we will bring a differentiated, oral targeted treatment to these patients with limited options across the globe," Dave Fredrickson, Executive Vice President of the Oncology Haematology Business Unit at AstraZeneca, said.
Sunvozertinib, also known as Zegfrovy, is approved in the U.S. and China for adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. About 77% of all lung cancers are NSCLC, according to the American Cancer Society. A late-stage multinational trial of 324 patients found median progression-free survival of 10.3 months for patients on sunvozertinib versus 7.5 months for those on chemotherapy.
Dizal is eligible for up to $900 million in additional payments tied to development and sales milestones, plus tiered royalties on global sales. The deal, expected to close in the second half of 2026, gives AstraZeneca a differentiated oral therapy for a patient population with limited targeted treatment options.
Approximately 80% to 85% of lung cancer patients globally have NSCLC, and about 10% to 15% of those in the U.S. and Europe carry EGFR mutations as a disease driver, compared with 30% to 40% in Asia. Roughly one in four patients with EGFR-mutated NSCLC has a tumor with an exon 20 insertion mutation or other atypical mutation where targeted options are scarce.
Sunvozertinib is the only oral targeted therapy for EGFR exon 20 insertion NSCLC approved in both the U.S. and China for patients after prior systemic therapy, Dizal Chief Executive Officer Xiaolin Zhang said. A supplemental new drug application for use in the first-line setting has been submitted to regulators in both countries, which have granted Breakthrough Therapy Designation.
The $600 million upfront payment confirms Dizal's drug development capabilities as cross-border pharma dealmaking between China and global players continues. For Dizal shareholders, the deal provides immediate capital and a path to milestone payments. The next catalyst is regulatory decisions on the first-line application in both China and the U.S.
This article is for informational purposes only and does not constitute investment advice.
